News

Kyverna, Verily team up to identify KYV-101 response biomarkers

Kyverna Therapeutics will use Verily Life Sciences’ high-resolution Immune Profiler to identify biomarkers to measure responses to KYV-101, Kyverna’s experimental cell therapy for lupus-related kidney disease. KYV-101 is being evaluated in an open-label trial, which is recruiting nine to 12 patients at clinical sites across the U.S.

Lupus Canada Catalyst Award aims to help predict treatment response

A Canadian researcher will use a newly granted Lupus Canada Catalyst Award — with one year of funding totaling $40,000 CAD (around $29,300) — for a study focused on better understanding the role of an inflammation marker in predicting treatment responses in people with lupus nephritis. Lupus nephritis is one…

Phase 2 trial of GLPG3667 for SLE now recruiting patients in US

Galapagos officially has launched a Phase 2 clinical trial that will test its oral therapy GLPG3667 — designed to ease disease severity in people with systemic lupus erythematosus (SLE) — at a half dozen sites in the U.S. The first participant has been randomized, or assigned to a treatment…

Walk to End Lupus Now fundraiser set for Sept. 9 in St. Louis

To raise money to battle lupus and increase awareness about the chronic autoimmune disorder, Allsup, which provides Social Security disability assistance, is again supporting the Lupus Foundation of America’s (LFA) annual Walk to End Lupus Now in St. Louis. Registration is required for the in-person event, set…

Trial will test AlloNK for SLE patients with lupus nephritis

AlloNK, an off-the-shelf experimental natural killer (NK) cell therapy being developed by Artiva Biotherapeutics, soon will enter clinical testing, in combination with rituximab, for systemic lupus erythematosus (SLE) patients with active lupus nephritis. This follows the approval of the company’s investigational new drug application by the U.S.

Phase 2b clinical trial seeks SLE patients with lupus nephritis

PALIZADE, a Phase 2b clinical trial of Kezar Life Sciences’ investigational therapy zetomipzomib, is still enrolling systemic lupus erythematosus (SLE) patients with active lupus nephritis, a severe lupus complication that causes kidney damage. The launch of the placebo-controlled PALIZADE trial (NCT05781750) earlier this year followed the completion…

For Black women with SLE, racial discrimination tied to inflammation

Racial discrimination was found to be associated with increased inflammation among Black women with systemic lupus erythematosus (SLE) in a recent study. Each experience of racial discrimination was tied to a nearly 4% increase in the levels of C-reactive protein (CRP), an inflammation marker, in the bloodstream, the findings…

Race, poverty, healthcare access influence disparities in lupus care

Disparities in lupus care and outcomes in the U.S. are influenced by structural and social determinants such as race, ethnicity, socioeconomics, education, and healthcare access. These are the findings of a study by the Lupus Foundation of America (LFA) through its Addressing health Inequities in Minorities (AIM)…

5 young scientists win Lupus Foundation of America support

The Lupus Foundation of America has announced this year’s winners of the Gina M. Finzi Memorial Student Summer Fellowship Program, designed to support students working in lupus research. Each award, worth $4,000, includes mentorship by an experienced researcher in the field of lupus. Winners, all young scientists, are pursuing…